Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (84)	4/21/2004 5:59:50 PM
From: mopgcw	Read Replies (1) \| Respond to of 276

GS report on Q: Stock rating: In-Line Coverage view: Neutral Small-Cap Growth Price: US$6.55 April 21, 2004 ILMN (IL/N): Q1 better w/ strong sales & higher margin. Turning profitable 2005. 52-Week Range US$10-2 YTD Price Change -7.09% Market Cap US$215.4mn ILMN reported a Q1 loss of $0.11, excluding a litigation related expense of $0.19MM, $0.05 better than our estimate due to higher revenues and better gross margin. In Q1/04, ILMN installed its seventh BeadLab system and started shipping its BeadStation system for medium throughout SNP genotyping. The company also started beta testing of its whole-genome gene expression Beadchip. We have revised our 2004 loss estimate to $0.37 from $0.46 based on higher revenue and improving gross margin. We expect ILMN to turn profitable in 2005 and introduce our 2005 EPS of $0.10. We continue to rate ILMN In-Line based on its broad technologies, rapid sales growth, and increasing dominance in the genotyping market. Risks to our view include weak demand from service customers, slower than expected sales, dependence on financial markets and litigation with ABI. Our coverage view remains Neutral. 1. 2004 MILESTONES a. Sign 20 genotyping service contracts b. Ship 20 genotyping systems, including BeadLabs and BeadStations- As of 3/31/04, shipped 3 systems (1 BeadLab and 2 BeadStations) c. Develop a minimum of 400,000 assays for the HapMap project d. Operating cash burn of less than $15MM- Cash reserves of $28MM as of 3/28/04 e. Ship whole-genome gene expression product- initiated beta testing during Q1/04, expect to start shipping by mid-year 2. Q1 LOSS OF $0.11/SHARE, $0.05 BETTER Total revenues of $10.8 million were $2.5MM higher than our forecast. Excluding $0.19MM of interest expense related to a litigation judgment, total expenses were $14.0MM. Gross margin of 74% was better than our forecast of 64% due to efficiency and improved product mix. R&D expenses were lower than our estimate primarily due to positive quarterly fluctuations. Other income of ($0.5MM) was $0.9M lower than our forecast due to lower cash and interest rate levels. The net loss, excluding the litigation charge of $0.19MM, was $4 million or $0.11 per share on 32.5 million basic shares. 3. REVISED 2004 LOSS ESTIMATE ON HIGHER REVENUES AND MARGIN; INTRODUCE 2005 EPS We raised our 2004 revenue forecast by $5MM to $44MM (+ 56% from 2003). We have boosted the gross margin to 71% from 66% to reflect continuing improvement in efficiency and better product mix with commercial introduction of the Sentrix BeadChip for whole genome expression in mid- 2004. We maintain our forecast for R&D expenses of $21.9MM but increased our SG&A expenses to $22.3MM from $20.4MM. The net impact was a revision in our 2004 loss estimate to $0.37 from $0.46. We expect Illumina to turn profitable in 2005 and introduced our EPS estimate of $0.10, based on revenues of $67MM (+ 51% over 2004), gross margin of 70%, and operating margin of 3%. 4. NEW PRODUCT LAUNCHES ON TRACK a. BeadStation 500G. In Q4/03, Illumina launched BeadStation 500G a benchtop instrument for genotype analysis by individual and core laboratories. The BeadStation allows 200,000 genotypes per day when used with the new Sentrix Arrays and cost $250,000 per system. During Q1/04, Illumina shipped its first two BeadStations. b. Gene expression product. In January 2004, Illumina announced its intent to offer two whole genome gene expression chips on its Sentrix BeadChip platform starting in mid-2004. One chip has the capacity to analyze six discrete whole human genomes at once, while the other can compare up to 8 samples in parallel against the 22,000 genes sequenced in a third party database. In the gene expression market, Illumina intends to target middle- market customers conducting experiments on 100-1,000 genes. Relative to the SNP genotyping systems, the gene expression systems can be installed more quickly thereby shortening the sales cycle versus the genotyping systems. In addition, Illumina is using its oligonucleotide sales force to sell its gene expression products, which should improve profitability. I, Maykin Ho, PhD, hereby certify..